Extended Data Fig. 6: Additional findings in BRAF-fused glioma in ages 0-40.

(A) Tumor location of BRAF fused glioma based on age of diagnosis in Toronto cohort (n = 207 patients). P-value calculated using Tukey’s multiple comparison test. (B) Age of diagnosis for KIAA1549-BRAF fusion vs non-canonical BRAF fusion partners in the Toronto cohort (n = 176 patients). P-value calculated using unpaired t-test (two-tailed). (C) Gene constructs of non-canonical BRAF fusions from AYA cohort. (D) BRAF fusion breakpoint/binding partner based on age of diagnosis in the Toronto cohort (n = 167 tumors). P-value calculated using one-way ANOVA, using Tukey’s multiple comparison test. (E) PFS and OS of BRAF fused glioma in the AYA cohort (including MSKCC cohort, n = 33 patients). P-value calculated using Log-rank test. (F) Multivariate analysis of factors influencing PFS in BRAF fused LGG. P-value calculated using Cox regression, error bars show 95% confidence intervals.